Cipla has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences (Inzpera). The company will pay a consideration of around Rs 110.65 crore for acquisition of equity shares and non-convertible redeemable preference shares, representing 100% of Inzpera’s shareholding.
Upon acquisition, Inzpera will become wholly owned subsidiary of the company. The acquisition is a strategic move aimed at combining Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with the company’s strong distribution network and operational capabilities to drive growth and scalability.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
